Barclays
TSVT

Barclays’s 2seventy bio TSVT Stock Holding History

Barclays’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77,347
Closed -$382K – 5544
2025
Q1 		$382K Sell
77,347
-13,448
-15% -$42.7K ﹤0.01% 3693
2024
Q4 		$267K Buy
90,795
+10,201
+13% +$41.8K ﹤0.01% 4170
2024
Q3 		$380K Sell
80,594
-132,019
-62% -$595K ﹤0.01% 3939
2024
Q2 		$819K Buy
212,613
+45,891
+28% +$207K ﹤0.01% 2722
2024
Q1 		$892K Buy
166,722
+83,170
+100% +$391K ﹤0.01% 3210
2023
Q4 		$357K Buy
83,552
+40,434
+94% +$124K ﹤0.01% 4096
2023
Q3 		$169K Sell
43,118
-79,660
-65% -$522K ﹤0.01% 3377
2023
Q2 		$1.24M Sell
122,778
-271,348
-69% -$2.87M ﹤0.01% 2171
2023
Q1 		$4.02M Buy
394,126
+317,124
+412% +$3.63M ﹤0.01% 1699
2022
Q4 		$722K Sell
77,002
-6,332
-8% -$89.3K ﹤0.01% 3055
2022
Q3 		$1.21M Buy
83,334
+79,198
+1,915% +$1.18M ﹤0.01% 2087
2022
Q2 		$55K Sell
4,136
-1,129
-21% -$15.4K ﹤0.01% 4004
2022
Q1 		$90K Buy
+5,265
New +$89.3K ﹤0.01% 3834

Other funds holding TSVT

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Barclays's TSVT Position: Q2 2025 in Review

Barclays sold out of 2seventy bio (TSVT) in Q2 2025, closing a stake of 77,347 shares — an estimated $382K sold.

Barclays first reported a position in TSVT in Q1 2022 and held it in 13 quarters. The position peaked at $4.02M in Q1 2023. 2 funds tracked by Wall St. Rank hold TSVT as of Q2 2025.

  • Barclays reported no remaining 2seventy bio position as of Q2 2025 after selling out during the quarter.
  • Barclays sold 77,347 2seventy bio shares in Q2 2025, an estimated $382K.
  • Barclays first reported a position in 2seventy bio in Q1 2022 and held it in 13 quarters.
  • Barclays's 2seventy bio position peaked at $4.02M in Q1 2023.
  • 2 funds tracked by Wall St. Rank held 2seventy bio as of Q2 2025.

Based on Barclays's 13F filing for Q2 2025, filed 13 Aug 2025.